CD71-mediated Liposomal Arsenic-nickel Complex Combined with All-trans Retinoic Acid for the Efficacy of Acute Promyelocytic Leukemia

Overview

Journal Asian J Pharm Sci

Date 2023 Aug 16

PMID 37583710

Authors

Xiao Liu

Lili Zhang

Yueying Yang

Weiwei Yin

Yunhu Liu

Chunyi Luo

Ruizhe Zhang

Zhiguo Long

Yanyan Jiang

Bing Wang

Affiliations

Soon will be listed here.

Abstract

Clinically, arsenic trioxide (ATO) was applied to the treatment of acute promyelocytic leukemia (APL) as a reliable and effective frontline drug. However, the administration regimen of As was limited due to its fast clearance, short therapeutic window and toxicity as well. Based on CD71 overexpressed on APL cells, in present study, a transferrin (Tf)-modified liposome (LP) was established firstly to encapsulate As in arsenic-nickel complex by nickel acetate gradient method. The As-loaded liposomes (AsLP) exhibited the feature of acid-sensitive release . Tf-modified AsLP (Tf-AsLP) were specifically taken up by APL cells and the acidic intracellular environment triggered liposome to release As which stimulated reactive oxygen species level and caspase-3 activity. Tf-AsLP prolonged half-life of As in blood circulation, lowered systemic toxicity, and promoted apoptosis and induced cell differentiation at lesion site . Considering that ATO combined with RA is usually applied as the first choice in clinic for APL treatment to improve the therapeutic effect, accordingly, a Tf-modified RA liposome (Tf-RALP) was designed to reduce the severe side effects of free RA and assist Tf-AsLP for better efficacy. As expected, the tumor inhibition rate of Tf-AsLP was improved significantly with the combination of Tf-RALP on subcutaneous tumor model. Furthermore, APL orthotopic NOD/SCID mice model was established by CO irradiation and HL-60 cells intravenously injection. The effect of co-administration (Tf-AsLP + Tf-RALP) was also confirmed to conspicuous decrease the number of leukemia cells in the circulatory system and prolong the survival time of APL mice by promoting the APL cells' apoptosis and differentiation in peripheral blood and bone marrow. Collectively, Tf-modified acid-sensitive AsLP could greatly reduce the systemic toxicity of free drug. Moreover, Tf-AsLP combined with Tf-RALP could achieve better efficacy. Thus, transferrin-modified As liposome would be a novel clinical strategy to improve patient compliance, with promising translation prospects.

References

McCulloch D, Brown C, Iland H . Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. Onco Targets Ther. 2017; 10:1585-1601. PMC: 5359123. DOI: 10.2147/OTT.S100513. View

Kozono S, Lin Y, Seo H, Pinch B, Lian X, Qiu C . Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018; 9(1):3069. PMC: 6085299. DOI: 10.1038/s41467-018-05402-2. View

Kumar S, Yedjou C, Tchounwou P . Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. J Exp Clin Cancer Res. 2014; 33:42. PMC: 4049373. DOI: 10.1186/1756-9966-33-42. View

Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando S, Iacobelli S . Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369(2):111-21. DOI: 10.1056/NEJMoa1300874. View

Shen Z, Chen G, Ni J, Li X, Xiong S, Qiu Q . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89(9):3354-60. View

Dadashzadeh S, Mirahmadi N, Babaei M, Vali A . Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge. J Control Release. 2010; 148(2):177-86. DOI: 10.1016/j.jconrel.2010.08.026. View

Frankel S, Eardley A, Lauwers G, Weiss M, Warrell Jr R . The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med. 1992; 117(4):292-6. DOI: 10.7326/0003-4819-117-4-292. View

Wang C, Zhang W, He Y, Gao Z, Liu L, Yu S . Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects. Nat Nanotechnol. 2021; 16(12):1413-1423. DOI: 10.1038/s41565-021-00980-7. View

Li Y, Ruan S, Guo J, He Z, Xia Q, Wu T . B16F10 Cell Membrane-Based Nanovesicles for Melanoma Therapy Are Superior to Hyaluronic Acid-Modified Nanocarriers. Mol Pharm. 2022; 19(8):2840-2853. DOI: 10.1021/acs.molpharmaceut.2c00212. View

10.

Yedjou C, Tchounwou P, Jenkins J, McMurray R . Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol. 2010; 3:28. PMC: 2939535. DOI: 10.1186/1756-8722-3-28. View

11.

Zhang Y, Xia Q, Wu T, He Z, Li Y, Li Z . A novel multi-functionalized multicellular nanodelivery system for non-small cell lung cancer photochemotherapy. J Nanobiotechnology. 2021; 19(1):245. PMC: 8364713. DOI: 10.1186/s12951-021-00977-3. View

12.

Adams J, Nassiri M . Acute Promyelocytic Leukemia: A Review and Discussion of Variant Translocations. Arch Pathol Lab Med. 2015; 139(10):1308-13. DOI: 10.5858/arpa.2013-0345-RS. View

13.

Chen H, MacDonald R, Li S, Krett N, Rosen S, OHalloran T . Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J Am Chem Soc. 2006; 128(41):13348-9. DOI: 10.1021/ja064864h. View

14.

Powell J, Lewis A, Zhu W, Toubia J, Pitman M, Wallington-Beddoe C . Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood. 2016; 129(6):771-782. PMC: 7484978. DOI: 10.1182/blood-2016-06-720433. View

15.

Wang P, Tang Z, Lee B, Zhu J, Cai L, Szalaj P . Chromatin topology reorganization and transcription repression by PML-RARα in acute promyeloid leukemia. Genome Biol. 2020; 21(1):110. PMC: 7212609. DOI: 10.1186/s13059-020-02030-2. View

16.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M . Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2016; 35(6):605-612. DOI: 10.1200/JCO.2016.67.1982. View

17.

Huang M, Ye Y, Chen S, Chai J, Lu J, Zhoa L . Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988; 72(2):567-72. View

18.

Hoonjan M, Jadhav V, Bhatt P . Arsenic trioxide: insights into its evolution to an anticancer agent. J Biol Inorg Chem. 2018; 23(3):313-329. DOI: 10.1007/s00775-018-1537-9. View

19.

Zhang X, Yan X, Zhou Z, Yang F, Wu Z, Sun H . Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 2010; 328(5975):240-3. DOI: 10.1126/science.1183424. View

20.

Burnett A, Russell N, Hills R, Bowen D, Kell J, Knapper S . Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015; 16(13):1295-305. DOI: 10.1016/S1470-2045(15)00193-X. View